Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers

Journal of Clinical Pharmacology

Volumn 57, Issue 2, 2017, Pages 185-193

  Asher, Gary N ^a   Xie, Ying ^b   Moaddel, Ruin ^c   Sanghvi, Mitesh ^c   Dossou, Katina S S ^c   Kashuba, Angela D M ^d   Sandler, Robert S ^a   Hawke, Roy L ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

clinical trial; curcumin; human; pharmacokinetics; steady state

Indexed keywords

CURCUMIN; CURCUMINOID; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; HEXAHYDROCURCUMIN; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG; GLUCURONIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXPOSURE; DRUG FORMULATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INTESTINE MUCOSA; MALE; MORNING DOSAGE; MULTICENTER STUDY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RECTUM; STEADY STATE; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; BIOTRANSFORMATION; CLASSIFICATION; INTESTINE ABSORPTION; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CROSS-OVER STUDIES; CURCUMIN; FEMALE; GLUCURONIDES; HEALTHY VOLUNTEERS; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; RECTUM; YOUNG ADULT;

EID: 84986268630     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.806     Document Type: Article

References (22)

1. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products. Exeter, UK: Thieme: 2003.
2. Asher GN, Spelman K. Clinical utility of curcumin extract. Altern Ther Health Med. 2013;19(2):20–22.
3. Sandur SK, Pandey MK, Sung B, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis. 2007;28(8):1765–1773.
4. Metzler M, Pfeiffer E, Schulz SI, Dempe JS. Curcumin uptake and metabolism. Biofactors. 2013;39(1):14–20.
5. Hoehle SI, Pfeiffer E, Solyom AM, Metzler M. Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver. J Agric Food Chem. 2006;54(3):756–764.
6. Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol.Biomarkers Prev. 2005;14(1):120–125.
7. Irving GR, Howells LM, Sale S, et al. Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration-a clinical pilot study including assessment of patient acceptability. Cancer Prev Res (Phila). 2013;6(2):119–128.
8. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett. 2008;267(1):133–164.
9. Kanai M, Imaizumi A, Otsuka Y, et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol. 2012;69(1):65–70.
10. Storka A, Vcelar B, Klickovic U, et al. Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. Int J Clin Pharmacol Ther. 2015;53(1):54–65.
11. Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod. 2011;74(4):664–669.
12. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol. 2007;60(2):171–177.
13. Clark AM, Pellock JM, Holmay M, Anders B, Cloyd J. Clinical utility of topiramate extended-release capsules (USL255): bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes. Epilepsy Behav. 2016;57(Pt A):105–110.
14. Youssef NN, Tron E, Tolia V, Hamer-Maansson JE, Lundborg P, Illueca M. Single-dose pharmacokinetic properties of esomeprazole in children aged 1–11 years with endoscopically proven GERD: a randomized, open-label study. Int J Clin Pharmacol Ther. 2014;52(11):965–972.
15. Wytiaz V, Homko C, Duffy F, Schey R, Parkman HP. Foods provoking and alleviating symptoms in gastroparesis: patient experiences. Dig Dis Sci. 2015;60(4):1052–1058.
16. Keku TO, Lund PK, Galanko J, Simmons JG, Woosley JT, Sandler RS. Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2076–2081.
17. Martin C, Connelly A, Keku TO, et al. Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology. 2002;123(6):1770–1777.
18. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev. 2009;14(3):226-246.
19. Pfeiffer E, Hoehle SI, Walch SG, Riess A, Solyom AM, Metzler M. Curcuminoids form reactive glucuronides in vitro. J Agric Food Chem. 2007;55(2):538–544.
20. Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC.Complement Altern Med. 2006;6:10.
21. Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660–665.
22. Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1411–1417.